The use of structurally modifying molecules in degenerative-dystrophic diseases of the spine remains a topical issue in neurological practice. Objective: to evaluate the efficacy of the combined use of structurally modifying molecules, namely FORTIGEL — proFLEX^®, drinking collagen hydrolysate BONNY Chondro, a complex of glycosaminoglycans and methylsulfonylmethane SAM-e 400, an endogenous chondroprotector, in patients with degenerative-dystrophic diseases of the spine. Methods. The study included 32 patients (15 men, 17 women) aged 36 to 81 years (mean age 54.64±2.34 years) with the duration of pain from 1 week to 25 years (mean duration 5.59±1.45 years). The examined women suffered from pain 3.4 times longer than men (8.64±2.41 and 2.55±1.07 years, respectively; p<0.03). All patients received structurally modifying molecules according to the following three-step scheme: step 1 — SAM-e 400, 1 tablet 2 times a day for 1 month, step 2 — BONNY Chondro, 1 stick a day for 3 months after SAM-e 400, step 3 — proFLEX^®, 1 vial once a day for 3 months. As steps 2 and 3 were performed in parallel, the total course of treatment was 4 months. Results. 4 months after administration of the proposed SYSADOA scheme, both the Visual analog scale and the Roland — Morris Disability Questionnaire score significantly decreased in the study group, with no difference between men and women. The Roland — Morris Disability Questionnaire score disability degree decreased 2 times (p<0.001) in the group as a whole, with women — 2 times, and men — 1.8 times (p<0.001). That is, treatment led to improved quality of life by reducing degree of disability, as evidenced by a decrease in complaints of pain in the study group by 51.75±2.56%, among women — by 51.74±3.84%, among men — by 51.77±3.51%.